X4 Pharmaceuticals' (XFOR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR - Free Report) in a report released on Friday,Benzinga reports. HC Wainwright currently has a $1.50 price target on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals' FY2028 earnings at $0.02 EPS and FY2029 earnings at $0.16 EPS.

Separately, Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR traded down $0.04 during trading on Friday, reaching $0.47. 2,189,131 shares of the company traded hands, compared to its average volume of 6,061,188. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a 50 day simple moving average of $0.60 and a 200-day simple moving average of $0.60. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The stock has a market capitalization of $79.82 million, a PE ratio of -5.22 and a beta of 0.12.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of the business's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 202,663 shares of company stock valued at $91,198. Company insiders own 1.62% of the company's stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XFOR. Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at approximately $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter valued at $37,000. Atria Wealth Solutions Inc. acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $44,000. XTX Topco Ltd raised its stake in X4 Pharmaceuticals by 41.7% in the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after acquiring an additional 46,397 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company's stock worth $166,000 after acquiring an additional 126,296 shares during the period. Hedge funds and other institutional investors own 72.03% of the company's stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.